AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

What symbol and exchange does Aim Immunotech shares trade?

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

What is Aim Immunotech stock price doing today?

As of November 14, 2025, AIM stock price declined to $1.41 with 35,281 million shares trading.

What is Aim Immunotech's Beta?

AIM has a beta of 8.65, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.27 to the broad based SPY ETF.

How much is Aim Immunotech worth?

AIM has a market cap of $3.90 million. This is considered a Sub-Micro Cap stock.

How much money does Aim Immunotech make?

Last quarter Aim Immunotech reported $25,000 in Revenue and -$3.68 earnings per share. This fell short of revenue expectation by $-75,000 and exceeded earnings estimates by $4.32.

What are the support and resistance levels for Aim Immunotech (AIM)?

AIM support price is $1.37 and resistance is $1.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.